Skip to main content
NEUROTECH INTERNATIONAL LIMITED logo

NEUROTECH INTERNATIONAL LIMITED — Investor Relations & Filings

Ticker · NTI ISIN · AU000000NTI9 ASX Professional, scientific and technical activities
Open in API
Filings indexed 667 across all filing types
Latest filing 2023-01-30 Capital/Financing Update
Country AU Australia
Listing ASX NTI

About NEUROTECH INTERNATIONAL LIMITED

https://neurotechinternational.com/

Neurotech International Limited is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapeutics for neurodevelopmental and neurological disorders. The company specializes in neuroprotective therapies, primarily targeting pediatric conditions with significant unmet medical needs, including Autism Spectrum Disorder (ASD), Pediatric Autoimmune Neuropsychiatric Disorders Associated with Streptococcal Infections (PANDAS), and Pediatric Acute-onset Neuropsychiatric Syndrome (PANS). Its lead drug candidate, NTI164, is a proprietary, broad-spectrum cannabinoid formulation derived from a unique cannabis strain. NTI164 is engineered to exert anti-inflammatory and neuroprotective effects by modulating neuroinflammatory pathways. The company conducts clinical trials to establish the safety and efficacy of its treatments, aiming to provide transformative behavioral and functional improvements for patients.

Recent filings

Filing Released Lang Actions
Secondary Trading Notice 1 page 92.8KB
Capital/Financing Update Classification · 95% confidence The document is an ASX announcement dated 31 January 2023. It is titled 'Secondary Trading Notice Pursuant to Section 708A(5)(e) of the Corporations Act' and discusses the issuance of ordinary fully paid shares without disclosure under Part 6D.2 of the Corporations Act. The notice confirms compliance with relevant sections of the Corporations Act and states there is no excluded information to disclose. The document is short (2725 characters) and is a regulatory announcement about share issuance and compliance, not a full financial report or detailed capital raising document. It does not contain financial statements or detailed analysis but is a formal regulatory notice related to capital changes. This fits best under Capital/Financing Update (CAP) as it relates to share issuance and compliance with disclosure requirements under the Corporations Act.
2023-01-30 English
Quarterly Activities/Appendix 4C Cash Flow Report 10 pages 725.4KB
Interim / Quarterly Report Classification · 95% confidence The document is titled 'Quarterly Activities Report for the period ending 31 December 2022' and includes detailed clinical updates, corporate activity, financial commentary including operating expenses, cash flow, capital raising, and R&D tax rebate. It also references an Appendix 4C Quarterly Cash Flow Report, which is a standard quarterly report for Australian listed entities. The document contains substantive financial data and analysis for a quarter, not just an announcement or a brief summary. It also mentions a conference call related to the quarterly report. The length is about 15,000 characters, indicating a full report rather than a short announcement. Therefore, this document fits the definition of an Interim / Quarterly Report (IR). Q2 2022
2023-01-29 English
HREC Approval for Phase I/II PANDAS/PANS Clinical Trial 6 pages 203.6KB
Regulatory Filings Classification · 95% confidence The document is an ASX announcement dated 27 January 2023 from Neurotech International Limited. It announces the receipt of Human Research Ethics Committee (HREC) approval and Clinical Trial Notification (CTN) clearance to commence a Phase I/II clinical trial for a drug (NTI164) targeting PANDAS/PANS disorders. The document details the clinical trial design, endpoints, inclusion/exclusion criteria, and safety monitoring. It is a regulatory announcement about the initiation of a clinical trial rather than a financial report, earnings release, or management discussion. It does not contain financial statements or results, nor is it a report publication announcement or certification. The content is primarily an operational update on clinical trial approval and plans, which fits best under Regulatory Filings (RNS) as a general regulatory announcement that does not fit other specific categories.
2023-01-26 English
Notice of Quarterly Investor Conference Call 2 pages 102.0KB
Regulatory Filings Classification · 95% confidence The document is an ASX announcement dated 24 January 2023, titled 'Notice of Quarterly Investor Conference Call.' It announces the upcoming release of the Appendix 4C Cash Flow Report and Management Quarterly Activities Report for the quarter ended 31 December 2022, and provides details for an investor conference call scheduled for 30 January 2023. The document does not contain actual financial statements or substantive financial data but rather serves as a notice for an event and report release. The document length is 3563 characters, which is relatively short and consistent with an announcement rather than a full report. Therefore, according to the 'Menu vs Meal' rule, this document is best classified as a Regulatory Filing (RNS) because it is a general regulatory announcement about an upcoming report and conference call, not the report itself or a transcript of the call.
2023-01-23 English
Application for quotation of securities - NTI 8 pages 29.6KB
Share Issue/Capital Change Classification · 100% confidence The document is an application for quotation of securities on the ASX, detailing the issuance of new shares due to the exercise of options or conversion of convertible securities. It includes specifics about the number of securities, issue dates, and the nature of the securities being quoted. There is no financial report, earnings data, management discussion, or regulatory certification. The document is an announcement related to capital changes, specifically the issuance and quotation of new shares following option exercises. This fits the category of Share Issue/Capital Change (SHA). The document length is sufficient and contains detailed information about the securities issued, confirming it is not a mere announcement of a report but a substantive filing about capital changes.
2023-01-23 English
Secondary Trading Notice 1 page 92.8KB
Capital/Financing Update Classification · 95% confidence The document is an ASX announcement dated 24 January 2023. It is titled 'Secondary Trading Notice Pursuant to Section 708A(5)(e) of the Corporations Act' and discusses the issuance of ordinary fully paid shares without disclosure under Part 6D.2 of the Corporations Act. The content focuses on compliance with regulatory provisions and disclosure obligations related to share issuance. There are no financial statements, earnings data, management discussion, or detailed report content. The document is short (2717 characters) and serves as a regulatory notice about a capital transaction rather than a full report or detailed financial disclosure. This fits the category of Capital/Financing Update (CAP), which covers updates on company fundraising, financing activities, or capital structure changes.
2023-01-23 English

Browse filings by year

11 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.